NEUP Neuphoria Therapeutics Inc.
Healthcare$5.46-0.33%ClosedMarket Cap: $29.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.01
P/S
-2.83
EV/EBITDA
-0.45
DCF Value
$50.44
FCF Yield
200.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
101.6%
Operating Margin
255.7%
Net Margin
263.1%
ROE
-109.7%
ROA
-79.2%
ROIC
-79.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 null | $0.00 | -Infinity% | $-1.8M | $-505.1K | $— | — |
| Q2 null | $0.00 | NaN% | $-6.1M | $2.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-8.6M | $-15.0M | $— | — |
| Q4 null | $-10.5M | 100.0% | $-10.4M | $-14.9M | $— | — |
| FY null | $15.6M | 100.0% | $-1.1M | $-369.6K | $— | — |
| Q3 null | $25.1M | 100.0% | $20.0M | $18.8M | $— | — |
| Q2 null | $1.1M | 100.0% | $-5.5M | $-3.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-5.3M | $-1.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-8.2M | $-4.0M | $— | — |
| FY null | $0.00 | NaN% | $-26.8M | $-23.2M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-3.7M | $-4.3M | $— | — |
| Q2 2024 | $0.00 | NaN% | $-6.7M | $-6.7M | $-0.03 | — |